Your browser doesn't support javascript.
loading
Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
Takoi, Hiroyuki; Togashi, Yuki; Fujimori, Daiki; Kaizuka, Haruki; Otsuki, Shunsuke; Wada, Takuya; Takeuchi, Yoshikazu; Abe, Shinji.
Afiliação
  • Takoi H; Department of Respiratory Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: taco155485@hotmail.com.
  • Togashi Y; Department of Respiratory Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: togashiy@tokyo-med.ac.jp.
  • Fujimori D; Department of Rheumatology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: fujimorifugusashifugufugu@yahoo.co.jp.
  • Kaizuka H; Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: fj0e.h.k@gmail.com.
  • Otsuki S; Department of Hematology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: i4112356@gmail.com.
  • Wada T; Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: wwwtk0820@yahoo.co.jp.
  • Takeuchi Y; Department of Cardiology and Division of Preemptive Medicine for Vascular Damage, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: yoshi.c603@gmail.com.
  • Abe S; Department of Respiratory Medicine, Tokyo Medical University, 6-7-1 Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Tokyo, Japan. Electronic address: sabe@tokyo-med.ac.jp.
Int J Infect Dis ; 101: 188-190, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32992014
ABSTRACT
Favipiravir, an antiviral agent, is undergoing clinical trials for treating novel coronavirus disease 2019 (COVID-19). Here, we report two cases of COVID-19 with favipiravir-induced fever. In both cases, pyrexia was observed following the administration of favipiravir despite improvements in symptoms of COVID-19. No other cause for fever was evident after careful physical examination and laboratory investigation. The fever subsided in both patients after the discontinuation of favipiravir. To the best of our knowledge, this is the first report of favipiravir-induced fever in COVID-19 patients.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Pirazinas / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Febre / Amidas / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Adult / Female / Humans / Male Idioma: En Revista: Int J Infect Dis Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Pirazinas / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Febre / Amidas / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Limite: Adult / Female / Humans / Male Idioma: En Revista: Int J Infect Dis Ano de publicação: 2020 Tipo de documento: Article